Nanosphere to Release Positive Pilot Study Data for Ultra-Sensitive Protein Cancer Biomarkers in Conjunction With the American Society of Clinical Oncology 2011 Annual Meeting

Nanosphere, Inc. NSPH announced today that it will release early stage research data on potential cancer biomarkers requiring high sensitivity in an abstract for the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from June 3 to 7, 2011. The early data suggests that three of Nanosphere's ultra-sensitive protein assays demonstrate potential clinical relevance in bladder, kidney and prostate cancers. The assays were developed and run using the Verisens™ high-throughput research platform.